@Woodz13, I've been accumulating at various prices over the past...

@Woodz13, I've been accumulating at various prices over the past 3 days: 4.2c, 4.3c, and 4.4c. I now hold a fairly substantial position. The best strategy is to let sellers sell down into your buy orders. A single large at-market order would push the share price up too much and increase ones aep. Yet, multiple at-limit buy orders sequentially placed into the market over a few days allow a large position to be built at a low aep.

Hope that provides more clarity

----------------------------------------------------------

@mbot, The atopic dermatitis (AD) asset (BTX1204) was awarded a risk adjusted valuation (NPV) of $34.3m compared to the total valuation of $285.3m by Argonaut Equity Research in the 3rd of February 2020 report. Given that the BTX1204 trial is not progressing, it naturally follows that the Arognaut share price target should be adjusted from 29 cents to 27 cents ($295.3m - $34.3m / 973). Not an issue at all.

T.E.P.